Company news

Atossa Therapeutics, Inc. news

Latest news releases, newest first. Pick a year for every news release, call and deck from that year.

View company

Atossa Therapeutics President and CEO Dr. Steven C. Quay Issues Annual Letter to Stockholders Highlighting Key Accomplishments and Strategy for 2021

February 9, 2021

Atossa Therapeutics Announces Two-Year Update of FDA-Approved Expanded Access Treatment with Endoxifen

February 2, 2021

Atossa Therapeutics’ Phase 2 Endoxifen Breast Cancer Study Produces Substantially Positive Results Allowing Study to be Halted Early

February 1, 2021

Atossa Therapeutics Announces Pricing of $25.2 Million Registered Direct Offering Priced At-The-Market

January 5, 2021

Atossa Therapeutics Announces Pricing of $14.0 Million Registered Direct Offering Priced At-The-Market

December 16, 2020

Atossa Therapeutics Announces Pricing of $20.0 Million Underwritten Public Offering

December 7, 2020

Atossa Therapeutics Announces Third Quarter 2020 Financial Results and Provides Corporate Update

November 12, 2020

Atossa Therapeutics Announces Preliminary Results from Phase 1 Clinical Study Showing Safety and Tolerability of AT-301 Nasal Spray Being Developed for COVID-19

November 9, 2020

Atossa Therapeutics Completes Enrollment of Phase 1 Clinical Study of AT-301 Nasal Spray Being Developed for the Coronavirus Causing COVID

October 18, 2020

Atossa Therapeutics Receives Second Positive Interim Safety Assessment in Clinical Study of AT-301 Nasal Spray Being Developed for the Coronavirus Causing COVID

September 16, 2020

Atossa Therapeutics Announces Positive Interim Safety Assessment of First Group of Participants in Clinical Study of AT-301 Nasal Spray Being Developed for COVID-19

August 31, 2020

Atossa Therapeutics Announces Enrollment and Dosing Completed in First Group of Healthy Participants in Clinical Study of AT-301 Nasal Spray Being Developed for Treatment of COVID-19

August 16, 2020

Atossa Therapeutics Announces Second Quarter 2020 Financial Results and Provides Corporate Update

August 12, 2020

Atossa Therapeutics Receives Approval to Open Clinical Study of AT-301 Nasal Spray Being Developed to Treat COVID-19

August 2, 2020

Atossa Therapeutics Announces Findings from FDA-Approved Expanded Access Treatment with Endoxifen

July 29, 2020

Atossa Therapeutics Contracts for Clinical Study of AT-301 Nasal Spray, Atossa’s Second COVID-19 Therapeutic Development Program

July 15, 2020

Atossa Therapeutics Announces Successful In Vitro Testing of Nasal Spray Formulation: AT-301 Inhibits SARS-CoV-2 Infectivity of VERO Cells in Laboratory Culture

July 14, 2020

Atossa Therapeutics Advances Product Development Programs with Multiple Key Hires in Clinical, Regulatory, and Chemistry Manufacturing and Controls

July 7, 2020

Atossa Therapeutics Announces Availability of Manuscript on Results from In vitro Testing of COVID-19 Drug, AT-H201

June 10, 2020

Atossa Therapeutics Announces Second COVID-19 Therapeutic Development Program, AT-301 Nasal Spray: Summit Biosciences Retained to Develop and Supply AT-301 Nasal Spray for Clinical Study

May 27, 2020

Atossa Therapeutics Announces Successful In vitro Testing Results of COVID-19 Drug: AT-H201 Inhibits SARS-CoV-2 Infectivity of VERO Cells in Laboratory Culture

May 19, 2020

Atossa Therapeutics Announces First Quarter 2020 Financial Results and Provides Company Update on COVID-19 HOPE and Endoxifen Programs

May 12, 2020

Atossa Therapeutics Announces Positive Interim Phase 2 Data from Endoxifen Breast Cancer Treatment

May 6, 2020

Atossa Therapeutics Contracts with NYC Health + Hospitals/Metropolitan for COVID-19 HOPE Clinical Study

April 26, 2020

Atossa Therapeutics Seeks Clinical Investigation Approval from FDA to Launch the COVID-19 HOPE Study

April 19, 2020

Atossa Therapeutics Launches COVID-19 HOPE Drug Development Program

April 15, 2020

Atossa Therapeutics Announces Clinical Progress

April 1, 2020

Atossa Therapeutics Announces Fourth Quarter and Year End 2019 Financial Results and Provides Company Update

March 25, 2020

Atossa Therapeutics Announces Upcoming Meeting with FDA

March 12, 2020

Atossa Therapeutics, Inc. Files for Swedish Regulatory Approval to Initiate a Phase 2 Study of Oral Endoxifen to Reduce Mammographic Breast Density

March 1, 2020

Atossa Genetics Announces Phase 2 Study Contract for Oral Endoxifen to Reduce Mammographic Breast Density in Women

December 18, 2019

Atossa Genetics to Present at the LD Micro 12th Annual Main Event on December 10, 2019

December 4, 2019

Atossa Genetics Announces Third Quarter 2019 Financial Results and Provides Company Update

November 12, 2019

Atossa Genetics Receives IRB Approval for Phase 2 Breast Cancer Study Using Intraductal Technology

October 15, 2019

Atossa Genetics Announces Preliminary Results from Phase 1 Study of Modified-Release Tablet Oral Endoxifen

September 29, 2019

← Newer news releases

Calls

Decks

The 5 newest of 9 decks. Every deck is listed under its year.